Literature DB >> 8356085

Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.

A Takashima1, K Noguchi, K Sato, T Hoshino, K Imahori.   

Abstract

Pathological changes of Alzheimer disease are characterized by cerebral cortical atrophy as a result of degeneration and loss of neurons. Typical histological lesions include numerous senile plaques composed of deposits of amyloid beta-protein and neurofibrillary tangles consisting predominantly of ubiquitin and highly phosphorylated tau proteins. Previously, tau protein kinase I (TPK I) was purified and its cDNA was cloned. To examine the biological role of this enzyme in neurons, we have studied the induction of its kinase activity in primary cultures of embryonic rat hippocampal neurons. Treatment of cultures with amyloid beta-protein significantly increased TPK I activity and induced the appearance of tau proteins recognized by the Alz-50 monoclonal antibody. In addition, though amyloid beta-protein was neurotoxic, either cycloheximide or actinomycin D prevented neuronal death. Death was also prevented by TPK I antisense oligonucleotides but not by sense oligonucleotides. These observations suggest that rat hippocampal neurons undergo programmed cell death in response to amyloid beta-protein and that TPK I is a key enzyme in this process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356085      PMCID: PMC47228          DOI: 10.1073/pnas.90.16.7789

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Mutations in APP and their role in beta-amyloid deposition.

Authors:  L Fidani; A Goate
Journal:  Prog Clin Biol Res       Date:  1992

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  A serine/threonine proline kinase activity is included in the tau protein kinase fraction forming a paired helical filament epitope.

Authors:  K Ishiguro; A Omori; K Sato; K Tomizawa; K Imahori; T Uchida
Journal:  Neurosci Lett       Date:  1991-07-22       Impact factor: 3.046

4.  Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments.

Authors:  K Ishiguro; M Takamatsu; K Tomizawa; A Omori; M Takahashi; M Arioka; T Uchida; K Imahori
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

5.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.

Authors:  N W Kowall; M F Beal; J Busciglio; L K Duffy; B A Yankner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

6.  Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage.

Authors:  J Y Koh; L L Yang; C W Cotman
Journal:  Brain Res       Date:  1990-11-19       Impact factor: 3.252

7.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity.

Authors:  M P Mattson; B Cheng; D Davis; K Bryant; I Lieberburg; R E Rydel
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

Review 8.  beta-Amyloid neurotoxicity: a discussion of in vitro findings.

Authors:  C W Cotman; C J Pike; A Copani
Journal:  Neurobiol Aging       Date:  1992 Sep-Oct       Impact factor: 4.673

9.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

Authors:  V M Lee; B J Balin; L Otvos; J Q Trojanowski
Journal:  Science       Date:  1991-02-08       Impact factor: 47.728

10.  Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons.

Authors:  A E Roher; M J Ball; S V Bhave; A R Wakade
Journal:  Biochem Biophys Res Commun       Date:  1991-01-31       Impact factor: 3.575

View more
  98 in total

1.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta.

Authors:  Minako Hoshi; Michio Sato; Shinichiro Matsumoto; Akihiko Noguchi; Kaori Yasutake; Natsuko Yoshida; Kazuki Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

3.  The Effects of Astilbin on Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Dongmei Wang; Sanqiang Li; Jing Chen; Ling Liu; Xiaoying Zhu
Journal:  Cell Mol Neurobiol       Date:  2016-07-19       Impact factor: 5.046

4.  Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Authors:  Manel G Medina; Maria Dolores Ledesma; Jorge E Domínguez; Miguel Medina; Delia Zafra; Francesc Alameda; Carlos G Dotti; Pilar Navarro
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

Review 5.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

Authors:  Eléonore Beurel; Richard S Jope
Journal:  Prog Neurobiol       Date:  2006-08-28       Impact factor: 11.685

Review 6.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 7.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

Review 8.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

9.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

Review 10.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.